Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
WTX-124 by Werewolf Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
WTX-124 is under clinical development by Werewolf Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
WTX-124 by Werewolf Therapeutics for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
WTX-124 is under clinical development by Werewolf Therapeutics and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC). According...
WTX-124 by Werewolf Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
WTX-124 is under clinical development by Werewolf Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase...
WTX-124 by Werewolf Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
WTX-124 is under clinical development by Werewolf Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...
WTX-124 by Werewolf Therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
WTX-124 is under clinical development by Werewolf Therapeutics and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....